
    
      The purpose of this study is to establish the safety profile and maximum tolerated dose (MTD)
      of the anti-IGF-IR monoclonal antibody IMC-A12 administered weekly in participants with
      advanced solid tumors who no longer respond to standard therapy or for whom no standard
      therapy is available
    
  